S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

SYRE Spyre Therapeutics Inc

32.53

0.00 (0.00%)

Pre Market

Last Updated: 19:00:00

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

10/25/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

04/16/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jeffrey W Albers

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Spyre Therapeutics (NASDAQ:SYRE)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Spyre Therapeutics Charts.

Spyre Therapeutics (NASDAQ:SYRE)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Spyre Therapeutics Charts.

Spyre Therapeutics Inc News

Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Thursday 31 October 2024 (2 days ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 29 October 2024 (3 days ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Saturday 26 October 2024 (6 days ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 24 October 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 15 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
Monday 14 October 2024 (3 weeks ago) • PR Newswire (US)

Spyre Therapeutics Announces Grants of Inducement Awards
Saturday 5 October 2024 (4 weeks ago) • PR Newswire (US)

Form EFFECT - Notice of Effectiveness
Thursday 3 October 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Wednesday 2 October 2024 (1 month ago) • Edgar (US Regulatory)

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
Tuesday 1 October 2024 (1 month ago) • PR Newswire (US)

Form S-3 - Registration statement under Securities Act of 1933
Saturday 21 September 2024 (1 month ago) • Edgar (US Regulatory)

More Spyre Therapeutics Inc News Articles

Woodside Petroleum

National Australia Bank

Invesco QQQ Trust Series 1

AUD vs US Dollar

S&P ASX 300 Metals and M...

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions